RhumbLine Advisers
CNST

RhumbLine Advisers’s Constellation Pharmaceuticals, Inc. CNST Stock Holding History

RhumbLine Advisers’s Portfolio CNST Stock Details CNST Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-52,829
Closed -$1.79M – 3063
2021
Q2 		$1.79M Buy
52,829
+17,435
+49% +$444K ﹤0.01% 2004
2021
Q1 		$828K Sell
35,394
-3,156
-8% -$95.6K ﹤0.01% 2277
2020
Q4 		$1.11M Buy
38,550
+2,454
+7% +$61.8K ﹤0.01% 2086
2020
Q3 		$731K Sell
36,096
-4,235
-11% -$103K ﹤0.01% 2118
2020
Q2 		$1.21M Buy
40,331
+16,357
+68% +$589K ﹤0.01% 1964
2020
Q1 		$754K Buy
23,974
+3,643
+18% +$127K ﹤0.01% 2005
2019
Q4 		$958K Buy
20,331
+471
+2% +$13.6K ﹤0.01% 2105
2019
Q3 		$128K Buy
19,860
+36
+0.2% +$301 ﹤0.01% 2847
2019
Q2 		$243K Buy
19,824
+3,512
+22% +$39.1K ﹤0.01% 2707
2019
Q1 		$221K Buy
+16,312
New +$146K ﹤0.01% 2711

RhumbLine Advisers's CNST Position: Q3 2021 in Review

RhumbLine Advisers sold out of Constellation Pharmaceuticals, Inc. (CNST) in Q3 2021, closing a stake of 52,829 shares — an estimated $1.79M sold.

RhumbLine Advisers first reported a position in CNST in Q1 2019 and held it in 10 quarters. The position peaked at $1.79M in Q2 2021. 0 funds tracked by Wall St. Rank hold CNST as of Q3 2021.

  • RhumbLine Advisers reported no remaining Constellation Pharmaceuticals, Inc. position as of Q3 2021 after selling out during the quarter.
  • RhumbLine Advisers sold 52,829 Constellation Pharmaceuticals, Inc. shares in Q3 2021, an estimated $1.79M.
  • RhumbLine Advisers first reported a position in Constellation Pharmaceuticals, Inc. in Q1 2019 and held it in 10 quarters.
  • RhumbLine Advisers's Constellation Pharmaceuticals, Inc. position peaked at $1.79M in Q2 2021.
  • 0 funds tracked by Wall St. Rank held Constellation Pharmaceuticals, Inc. as of Q3 2021.

Based on RhumbLine Advisers's 13F filing for Q3 2021, filed 12 Nov 2021.